Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

By S. Peeters, W. Heemsbergen, P. Koper, W. van Putten, A. Slot, M. Dielwart, J. Bonfrer, L. Incrocci, J. Lebesque. Journal of Clinical Oncology, 2006

998 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/eae60985742e063e3c126301cb8bff27d98d28a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. A. Heidenreich
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. V. Matveev
6. Steven Joniau
7. Thomas Wiegel

Citations in the corpus

• Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer (2008, background): “high-dose (78 Gy) EBRT (1 RCT) [27] Medium Trial 2: No benefit of high-dose EBRT among low-risk patients (freedom from treatment failure better in the high-dose group)”
• Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. (2008, methodology): “There has been no significant difference in GU toxicity greater than grade 2 or grade 3 between dose levels in any of the randomized studies (19, 20).”
• EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. (2011, background): “For intermediate-risk PCa, many series have shown a significant impact of dose escalation on 5-yr progressionfree survival in cT1c–T3 PCa, with a dose ranging from 76 to 81 Gy [72].”